December 20, 2005 -- Bayer and Onyx announced that the FDA approved Nexavar, their widely heralded, jointly produced drug for kidney cancer; Memory Pharma will get $3.2 million from the Stanley Medical Research Institute to develop its bipolar drug; Pharmion signed a deal with GPC Biotech of Germany for the non-North American rights to satraplatin, an oral platinum-based cancer treatment; Lexicon Genetics received $20 million from Genentech, representing two milestone payments; CuraGen modified its agreement with Bayer Pharma on a treatment for metabolic disorders; and Debiopharm and Dyax have altered their partnership arrangements over Depelestat, a treatment for pulmonary disorders. The Centient Biotech 200™ was up 28.5 points at 3899.54, a gain of .73%. More details...
